Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the level of calcium is little in blood and the phosphorus is high, due to which the human body show some sign which include muscle spasm, hair loss, dry skin, numbness, and seizures. Hypoparathyroidism occurs in both child and adults. If Hypoparathyroidism occurs in child it show some sign as poor tooth development, vomiting, headaches and mental disorders.
The present of Hypoparathyroidism in the body can be exam various test like PTH blood test, calcium blood test, also by ECG to check abnormal heart rhythm and also by CT scan to exam the deposition of calcium in brain. Hypoparathyroidism are most common problem now a days due to the lifestyle and eating habits.
Obtain Report Details @
Hypoparathyroidism Treatment Market: Drivers and Restraints
Hypoparathyroidism treatment market is estimated to be a big market over the forecast periods, as the current population over the globe are suffering from hypoparathyroidism, For instance, a report published by Endocrine Society in 2016, it was 60-8,000 patients in the U.S are suffering from hypoparathyroidism. Players are coming with new technology advancement for the treatment of hypoparathyroidism, For instance, in January 2015, Shire-NPS Pharmaceuticals, Inc. got approval from a product used for treatment of hypoparathyroidism name as NATPARA (parathyroid hormone) which is an injection for subcutaneous use. Current market are having less players which are working on hypoparathyroidism treatment. All the product in hypoparathyroidism come under pharmaceutical or directly connect to human, so it need to go under some clinical process and have to get the approval from the respective agency before going to commercializes in the market which is a restraints for the segment.
Hypoparathyroidism Treatment Market: Segmentation
Hypoparathyroidism Treatment segmentation based on
Based on Diagnosed Type:
- low blood calcium levels
- low blood PTH levels
- high blood phosphorus levels
Based on Mode of Treatment Type:
- Injection or subcutaneous infusion
- Surgery mode
Second line therapy
- Recombinant human parathyroid hormones (PTH)
- Dosing & monitoring
- Adverse effects
Based on End User:
- Endocrinologist Specialised treatment Clinic
- Ambulatory Surgical Centre
Hypoparathyroidism Treatment Market: Overview
Hypoparathyroidism treatment market have huge potentials for all the players are working or willing to work to come up with new product in this segments. For instance, in first quarter of 2015, Shire has purchased NPS Pharma in $5.2 Billion due to the product name as Natpara an injection used for the treatment of hypoparathyroidism. The population with hypoparathyroidism also show the high interest rate for getting the treatment. For instance, based on the publication by European Union (EU 28) in June 2016, less the 5 in 10,000 peoples in Europe Union is affected by hypoparathyroidism, which will be equivalent to total of fewer than 257,000 peoples. Many players also in process to make enters with their products into the market, as instance EnteraBio Ltd., is positively received an opinion in Europe market, and also currently focusing in the U.S.
Hypoparathyroidism Treatment Market: Region-wise Outlook
Geographically, Hypoparathyroidism Treatment Market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, Middle East and Africa. North America will be the potential market for the players as there is huge demand for the product, and the players are also coming with new product with proper FDA approval. Europe and Asia-Pacific is also a market where the players grow as the potentials.
Hypoparathyroidism Treatment Market: Key Players
Some of the players for Hypoparathyroidism Treatment Market are Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, EnteraBio Ltd., WCCT GLOBAL INC., Takeda Pharmaceutical Company Limited, Novartis AG, and GlaxoSmithKline plc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Fill the form for an exclusive sample of this report @
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.